drugset
drugset / Trial / NCT05239676

Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

NCT05239676 ↗

Phase 0 Unknown 50 enrolled Zhejiang University Yake Biotechnology Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

Clinical Study on the Safety and Effectiveness of Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

Timeline

Start
2022-02-28
Primary completion
2024-12-01
Completion
2024-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19 CAR-T cells Cell therapy — —

Indications

lymphoma